Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester

Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester

Described is a stable pharmaceutical composition of 3-(hydroxymethyl-5,5-diphenylhydantoin disodium phosphate ester, the prodrug of 5,5-diphenylhydantoin (phenytoin) a commonly used drug for the treatment and management of epilepsy and other types of convulsive states. It has been found that degrada...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ROSENBERG, LEONARD S, SPEICHER, EARL R, HERBRANSON, DALE E
Format: Patent
Sprache:nor
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ROSENBERG, LEONARD S
SPEICHER, EARL R
HERBRANSON, DALE E
description Described is a stable pharmaceutical composition of 3-(hydroxymethyl-5,5-diphenylhydantoin disodium phosphate ester, the prodrug of 5,5-diphenylhydantoin (phenytoin) a commonly used drug for the treatment and management of epilepsy and other types of convulsive states. It has been found that degradation of the prodrug to phenytoin can be controlled by controlling the pH of the composition. Controlling the pH to between 8.3 to 9.4 results in the production of diphenylglycinamide as the primary degradant and minimization of degradation to phenytoin. If the pH is maintained at a lower or higher value, then the degradation pattern changes, with earlier than expected product failure.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_NO179124CC</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>NO179124CC</sourcerecordid><originalsourceid>FETCH-epo_espacenet_NO179124CC3</originalsourceid><addsrcrecordid>eNqFizFuwkAQRd2kiEjOkC1BsgsCCFFboFShoUeTeNYM7M5aMxNLe4tcgitwAV8sRqJP9aT3_n8ufneCsQVuNQ5XQ-eTOD8qNQqBuHXQOzRHfCZF-QKx0vXADbWl8yARdLhlI724TrADAbs_FtX0lBtJF80RLYdZtSpXVUMeOYexAFsiHgWDCf1En9SDoRrKS_HkISi-Pjgp3nbbQ_1RYZeOqB18I6MdP_fz9Wb-vqzrxf-LP7pcUOE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester</title><source>esp@cenet</source><creator>ROSENBERG, LEONARD S ; SPEICHER, EARL R ; HERBRANSON, DALE E</creator><creatorcontrib>ROSENBERG, LEONARD S ; SPEICHER, EARL R ; HERBRANSON, DALE E</creatorcontrib><description>Described is a stable pharmaceutical composition of 3-(hydroxymethyl-5,5-diphenylhydantoin disodium phosphate ester, the prodrug of 5,5-diphenylhydantoin (phenytoin) a commonly used drug for the treatment and management of epilepsy and other types of convulsive states. It has been found that degradation of the prodrug to phenytoin can be controlled by controlling the pH of the composition. Controlling the pH to between 8.3 to 9.4 results in the production of diphenylglycinamide as the primary degradant and minimization of degradation to phenytoin. If the pH is maintained at a lower or higher value, then the degradation pattern changes, with earlier than expected product failure.</description><edition>6</edition><language>nor</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>1996</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19960814&amp;DB=EPODOC&amp;CC=NO&amp;NR=179124C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19960814&amp;DB=EPODOC&amp;CC=NO&amp;NR=179124C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ROSENBERG, LEONARD S</creatorcontrib><creatorcontrib>SPEICHER, EARL R</creatorcontrib><creatorcontrib>HERBRANSON, DALE E</creatorcontrib><title>Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester</title><description>Described is a stable pharmaceutical composition of 3-(hydroxymethyl-5,5-diphenylhydantoin disodium phosphate ester, the prodrug of 5,5-diphenylhydantoin (phenytoin) a commonly used drug for the treatment and management of epilepsy and other types of convulsive states. It has been found that degradation of the prodrug to phenytoin can be controlled by controlling the pH of the composition. Controlling the pH to between 8.3 to 9.4 results in the production of diphenylglycinamide as the primary degradant and minimization of degradation to phenytoin. If the pH is maintained at a lower or higher value, then the degradation pattern changes, with earlier than expected product failure.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1996</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFizFuwkAQRd2kiEjOkC1BsgsCCFFboFShoUeTeNYM7M5aMxNLe4tcgitwAV8sRqJP9aT3_n8ufneCsQVuNQ5XQ-eTOD8qNQqBuHXQOzRHfCZF-QKx0vXADbWl8yARdLhlI724TrADAbs_FtX0lBtJF80RLYdZtSpXVUMeOYexAFsiHgWDCf1En9SDoRrKS_HkISi-Pjgp3nbbQ_1RYZeOqB18I6MdP_fz9Wb-vqzrxf-LP7pcUOE</recordid><startdate>19960814</startdate><enddate>19960814</enddate><creator>ROSENBERG, LEONARD S</creator><creator>SPEICHER, EARL R</creator><creator>HERBRANSON, DALE E</creator><scope>EVB</scope></search><sort><creationdate>19960814</creationdate><title>Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester</title><author>ROSENBERG, LEONARD S ; SPEICHER, EARL R ; HERBRANSON, DALE E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_NO179124CC3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>nor</language><creationdate>1996</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ROSENBERG, LEONARD S</creatorcontrib><creatorcontrib>SPEICHER, EARL R</creatorcontrib><creatorcontrib>HERBRANSON, DALE E</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ROSENBERG, LEONARD S</au><au>SPEICHER, EARL R</au><au>HERBRANSON, DALE E</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester</title><date>1996-08-14</date><risdate>1996</risdate><abstract>Described is a stable pharmaceutical composition of 3-(hydroxymethyl-5,5-diphenylhydantoin disodium phosphate ester, the prodrug of 5,5-diphenylhydantoin (phenytoin) a commonly used drug for the treatment and management of epilepsy and other types of convulsive states. It has been found that degradation of the prodrug to phenytoin can be controlled by controlling the pH of the composition. Controlling the pH to between 8.3 to 9.4 results in the production of diphenylglycinamide as the primary degradant and minimization of degradation to phenytoin. If the pH is maintained at a lower or higher value, then the degradation pattern changes, with earlier than expected product failure.</abstract><edition>6</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language nor
recordid cdi_epo_espacenet_NO179124CC
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A43%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ROSENBERG,%20LEONARD%20S&rft.date=1996-08-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ENO179124CC%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true